×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BMY – bristol-myers squibb company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BMY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/15
06:42 am
bmy
JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]
Low
Report
JPM26: BioNTech gears up for multiproduct oncology status by 2030 [Yahoo! Finance]
1/15
06:42 am
bmy
Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]
Low
Report
Central Nervous System Therapeutic Market Report 2025-2033: Key Drivers, Regional Nuances, Competitive Dynamics | Astute Analytica [Yahoo! Finance]
1/14
01:01 pm
bmy
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]
Low
Report
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients [Yahoo! Finance]
1/14
12:12 pm
bmy
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]
Low
Report
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference [CNBC]
1/14
03:42 am
bmy
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
Low
Report
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]
1/13
08:47 pm
bmy
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release [Yahoo! Finance]
Low
Report
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release [Yahoo! Finance]
1/13
11:36 am
bmy
JPM26: J&J reveals oncology strategy [Yahoo! Finance]
Low
Report
JPM26: J&J reveals oncology strategy [Yahoo! Finance]
1/13
10:59 am
bmy
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
Low
Report
Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
-0.1%
bristol-myers squibb company
10/30/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
1.0%
bristol-myers squibb company
10/30/2025
09:06 am
bmy
bristol-myers squibb company
BEAT
Report
5.5%
bristol-myers squibb company
7/31/2025
04:03 pm
bmy
bristol-myers squibb company
BEAT
Report
2.1%
bristol-myers squibb company
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/12
10:21 am
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Jan 12
Low
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Jan 12
1/5
04:16 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: YALE PHYLLIS R
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: YALE PHYLLIS R
1/5
04:15 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Samuels Theodore R. II
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Samuels Theodore R. II
1/5
04:14 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Rice Derica W
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Rice Derica W
1/5
04:13 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: McMullen Michael R.
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: McMullen Michael R.
1/5
04:11 pm
bmy
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Arduini Peter J
Low
Report
Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Arduini Peter J
11/18
04:42 pm
bmy
Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 17
Medium
Report
Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 17
11/12
10:07 am
bmy
Form CERT BRISTOL MYERS SQUIBB CO
Low
Report
Form CERT BRISTOL MYERS SQUIBB CO
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/15
What Has Led Bristol-Myers Squibb's Stock To Fall More Than 35% Over The Last 3 Years? [Forbes]
2.7%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
7/24 Bristol-Myers releases mixed Opdivo lung cancer results [Reuters] 10.2%
4/20 Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma 2.8%
3/31 Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) to FDA 2.8%
8/25 Better Buy: Biogen vs. Celgene [The Motley Fool] 3.1%
4/3 Form 3 BRISTOL MYERS SQUIBB CO For: Mar 30 Filed by: Mily Elizabeth 3.4%
3/3 Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics for Oncology 3.9%
4/8 Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer 4.3%
3/25 Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05 5.9%
3/12 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: LEUNG SANDRA 7.9%
7/24 Bristol-Myers releases mixed Opdivo lung cancer results [Reuters] 10.2%
TOP News Decliners
4/20
Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool]
-3.5%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
6/24 Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma -7.8%
4/7 Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S. -3.6%
3/16 BMY Stock Dives As Investors Worry Coronavirus Could Delay A Key Drug [Investor's Business Daily] -3.6%
2/26 Form 4 BRISTOL MYERS SQUIBB CO For: Feb 03 Filed by: Metcalfe Kathryn -4.0%
3/18 Bristol Myers Squibb Appoints Elizabeth Mily as Executive Vice President, Strategy & Business Development -4.3%
3/20 Bristol-Myers Squibb, Sanofi strike out in bid to stop Plavix litigation [Seeking Alpha] -4.3%
3/6 Form 4 BRISTOL MYERS SQUIBB CO For: Mar 04 Filed by: Elicker John E -4.4%
10/22 Bristol-Myers' immunotherapies show promise in lung cancer trial; shares rise [Yahoo! Finance News] -4.9%
3/11 Nationwide class actions are safe, thanks to the D.C. and 7th Circuits [Reuters] -7.1%
6/24 Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: